A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically or cytologically confirmed Stage III B or Stage IV squamous non-small
cell lung cancer (NSCLC)

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- No prior chemotherapy for squamous NSCLC

- Adequate tissue for central IHC assay of Met receptor, and EGFR testing if EGFR
status is unknown

- Radiographic evidence of disease

Exclusion Criteria:

- Prior systemic treatment for Stage IIIB or IV squamous NSCLC

- NSCLC with histology classified as adenocarcinoma, large cell, mixed adenosquamous,
or NSCLC not otherwise specified (NOS)

- Prior exposure to experimental treatment targeting either the HGF or Met pathway

- Patients with tumors confirmed to have EGFR-activating mutations who are suitable for
anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator

- Uncontrolled brain metastases and treatment by neurosurgical resection or brain
biopsy within 4 weeks prior to Day 1 of Cycle 1

- History of another malignancy in the previous 3 years except for prior history of in
situ cancer or basal or squamous cell skin cancer

- Pregnant or lactating women

- Uncontrolled diabetes

- Impaired bone marrow, liver or renal function as defined by protocol

- Significant history of cardiovascular disease

- Positive for HIV infection